KnowBreastCancer StopBreastCancer Learn the Facts. Know the Evidence. Become an Advocate. Brought to you by NBCC
 

Category: Uncategorized

Anthracyclines

Does the evidence still support their use in the first-line treatment of breast cancer? The anthracycline debate continues. In 2007, the National Breast Cancer Coalition took the position that “for the vast majority of women with breast cancer, anthracycline-based chemotherapy is no more effective and has the potential for more serious toxicities than other known […]

Ductal Carcinoma In Situ (DCIS)

Is DCIS breast cancer? How should it be treated? Controversy over Name Cancer or carcinoma implies invasiveness and DCIS is specifically not invasive. Some scientists and medical professionals are calling for the removal of “carcinoma” from the name for the disease. Nomenclature was discussed at the National Institute of Health State-of-the-Science Conference: Diagnosis and Management […]

Trastuzumab (Herceptin®)

Who will benefit and what is the optimal treatment protocol? HER2 is short for Human Epidermal Growth Factor Receptor 2 (also be called Her-2/neu or ErbB2). All normal breast cells contain copies of the HER2 gene, which gives instructions to the cell on how to make the HER2 protein. The HER2 protein, also called the […]

HER2 Testing

Is HER2 testing accurately identifying breast cancer patients who would benefit from targeted therapy? What is HER2? HER2 (also Her-2/neu or ErbB2) stands for Human Epidermal Growth Factor Receptor 2, and is one of a family of several receptor proteins. All normal breast cells contain the HER2 gene, which gives instructions to the cell on […]

Researchers discover a rotational motion of cells that may have implications for future breast cancer research

Scientists with the U.S. Department of Energy’s Lawrence Berkeley National Laboratory have made a discovery that may have important implications for future breast cancer research. These findings are published in the Proceedings of the National Academy of Sciences. According to the research team led by Dr. Mina Bissell, human epithelial cells in the breast and […]

Two anti-HER2 drugs may be better than one in the neoadjuvant setting

The combination of trastuzumab and lapatinib, two drugs that inhibit HER2, may be better than treatment with either agent alone in the neoadjuvant (preoperative) setting, according to results of a study published in Lancet. “This is the first demonstration that adding a second anti-HER2 therapy, lapatinib, to trastuzumab is superior to trastuzumab alone in patients […]

Glossary

Absolute risk The risk is the chance that something will happen to you during a certain period of time. It is the number of people who would have the event if 100 people were observed. It is written as a percent (%). For instance, your risk of getting a disease in the next 5 years […]

FDA approves new drug for the treatment of HER2+ metastatic breast cancer

On June 8, the FDA approved Perjeta (pertuzumab), a new anti-HER2 therapy, to treat patients with HER2+ metastatic breast cancer. According to the FDA, the drug is intended for patients who have not received prior treatment for metastatic breast cancer with an anti-HER2 therapy or chemotherapy and is to be combined with trastuzumab, another anti-HER2 […]

Supplement on Breast Cancer

The Journal Nature released a supplement on breast cancer today, including two articles on breast cancer metastasis, one on redesigning clinical trials for metastasis, and another on the reality of metastasis, with a discussion of tumor dormancy. MYTHS VS. TRUTHS Brush up on your breast cancer myths and truths. Find out if you know more […]

“Rewiring” Cells to Treat Triple Negative Breast Cancer

Breast cancer cells can be “rewired” to make them more sensitive to chemotherapy, according to a new study published in the journal Cell. Rather than giving targeted therapy and chemotherapy simultaneously, researchers at the Massachusetts Institute of Technology (MIT) pretreated the cancer cells with targeted therapy, making them more susceptible to DNA-damaging chemotherapy. Dr. Michael […]